Emicizumab clinical trials
Also written Hemlibra, RO5534262 and ACE910.
How each study uses emicizumab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the emicizumab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 16 Nov 2017 · HEMLIBRA · BLA 761083 (FDA, Drugs@FDA)
- European Union
- 23 Feb 2018 · Hemlibra · EMEA/H/C/004406 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
26 studies that test it; most in 2021 (6)
| Year | Studies |
|---|---|
| 2015 | 1 |
| 2016 | 2 |
| 2017 | 2 |
| 2018 | 3 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 6 |
| 2022 | 4 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 2 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 13 · Other 13
Hoffmann-La Roche (11) · Indiana Hemophilia &Thrombosis Center, Inc. (2) · Margaret Ragni (2) · University of Washington (1) · GWT-TUD GmbH (1) · Cliniques universitaires Saint-Luc- Université Catholique de Louvain (1) · Versiti Blood Health (1) · Dhaka Medical College (1)
Often tested with
Tested in the same studies.
Preventive Intervention (1) · Fitusiran (1) · Anti-inhibitor coagulant complex (1) · Factor VIII-Fc fusion protein (1) · BAX 855 (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Tested against it · 1 phase 3 study under way
Emicizumab is the comparator. A study of two new drugs counts under both.
- 1NXT007 · Hoffmann-La Roche · next primary completion Feb 2028
Reaching primary completion within a year · 3, 1 in phase 3
Studies that test emicizumab, phase 3 first.
- Oct 2027A Study to Assess the Efficacy and Safety of Emicizumab in Participants With Type 3 Von Willebrand DiseasePhase 3 · Hoffmann-La Roche
- Nov 2026A Study to Evaluate Overall Health, Physical Activity, and Joint Outcomes in Participants With Severe or Moderate Hemophilia A Without Factor VIII Inhibitors on Emicizumab ProphylaxisPhase 4 · Hoffmann-La Roche
- Jun 2027Emicizumab for Severe Von Willebrand Disease (VWD) and VWD/Hemophilia APhase 1 · Bleeding and Clotting Disorders Institute Peoria, Illinois
Studies
Open first, then newest update. How each study uses emicizumab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 26
- A Study to Assess the Efficacy and Safety of Emicizumab in Participants With Type 3 Von Willebrand DiseaseRecruitingPhase 3Hoffmann-La RocheNCT06998524Written as Emicizumab
- A Study to Test a Medicine (Fitusiran) for Preventing Bleeds in People With Severe Hemophilia Who Previously Received Preventive Treatment With EmicizumabRecruitingPhase 4SanofiNCT06145373Written as Emicizumab
- Understanding Treatment Outcomes and Immunologic Mechanisms in Altuviiio Immune Tolerance InductionNot yet recruitingPhase 4Versiti Blood HealthNCT07158606Written as Emicizumab
- Emicizumab for Severe Von Willebrand Disease (VWD) and VWD/Hemophilia ARecruitingPhase 1Bleeding and Clotting Disorders Institute Peoria, IllinoisNCT05500807Written as Emicizumab
- Low Dose Emicizumab vs Low Dose Factor VIII in Prophylaxis in Hemophilia A PatientsNot yet recruitingPhase 2/3Dhaka Medical CollegeNCT06938659Written as Emicizumab Injection
- Hemlibra in Mild Hemophilia ARecruitingPhase 4Indiana Hemophilia &Thrombosis Center, Inc.NCT04567511Written as Emicizumab
- Comparison of Outcomes Between Low Dose Emicizumab and Factor VIII in Clinically Severe Hemophilia ARecruitingPhase 2/3Chulalongkorn UniversityNCT06155955Written as "Emicizumab", "HEMLIBRA®"
- SAFE Study: Safety of aPCC Following Emicizumab ProphylaxisWithdrawnPhase 3Emory UniversityNCT04563520Written as Emicizumab
- A Study to Evaluate Overall Health, Physical Activity, and Joint Outcomes in Participants With Severe or Moderate Hemophilia A Without Factor VIII Inhibitors on Emicizumab ProphylaxisActive, not recruitingPhase 4Hoffmann-La RocheNCT05181618Written as Emicizumab
- A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Emicizumab in Participants From Birth to 12 Months of Age With Hemophilia A Without InhibitorsActive, not recruitingPhase 3Hoffmann-La RocheNCT04431726Written as Emicizumab
- A Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Emicizumab in Participants With Mild or Moderate Hemophilia A Without FVIII InhibitorsCompletedPhase 3Hoffmann-La RocheNCT04158648Written as Emicizumab
- POCUS: Hemostatic Potential and Joint Health in Patients With Severe Hemophilia A on Novel Replacement TherapiesWithdrawnPhase 4University of Texas Southwestern Medical CenterNCT04690322Written as Emicizumab
- Efficacy, Safety, and Pharmacokinetic Study of Prophylactic Emicizumab Versus No Prophylaxis in Hemophilia A ParticipantsCompletedPhase 3Hoffmann-La RocheNCT03315455Written as Emicizumab
- Emicizumab in Patients With Acquired Hemophilia AActive, not recruitingPhase 2University of WashingtonNCT05345197Written as emicizumab
- HemLibra Prophylaxis in Patients With Hemophilic PseudotumorTerminatedPhase 4Indiana Hemophilia &Thrombosis Center, Inc.NCT03921294Written as Emicizumab
- The Hemophilia Inhibitor Prevention TrialTerminatedPhase 3Margaret RagniNCT04303559Written as Emicizumab Injection [Hemlibra]
- The Hemophilia Inhibitor Eradication TrialTerminatedPhase 3Margaret RagniNCT04303572Written as Emicizumab
- A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Emicizumab Given Every 4 Weeks in Participants With Hemophilia ACompletedPhase 3Hoffmann-La RocheNCT03020160Written as Emicizumab
- Emicizumab in Acquired Hemophilia ACompletedPhase 2GWT-TUD GmbHNCT04188639Written as Emicizumab Injection
- A Clinical Trial to Evaluate Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants Without InhibitorsCompletedPhase 3Hoffmann-La RocheNCT02847637Written as Emicizumab
See all 26 studies that test emicizumab →
Given beside what is tested · 2 — emicizumab is usual care or a partner of the new treatment
As the comparator · 1 — what is tested is compared with emicizumab
What changed recently
From the registry's own updates since Oct 18, 2026.
Stopped1
- SAFE Study: Safety of aPCC Following Emicizumab ProphylaxisWithdrawnNov 6, 2026NCT04563520
Codes
What other systems call emicizumab · ClinicalTrials.gg INT000473
- MeSH (NLM) C000608208emicizumabConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 7NL2E3F6K3EMICIZUMABConfirmed FDA, NLM, Wikidata
- RxNorm 1989794Confirmed FDA, Wikidata
- Wikidata Q27155409emicizumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C159541EmicizumabOne source FDA
- DrugBank DB13923One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000608208 | emicizumab | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 7NL2E3F6K3 | EMICIZUMAB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1989794 | — | Confirmed FDA, Wikidata |
| Wikidata | Q27155409 | emicizumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C159541 | Emicizumab | One source FDA |
| DrugBank | DB13923 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.